# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k063272   
B. Purpose for Submission: New devices   
C. Measurand: Human $\beta _ { 2 }$ -microglobulin   
D. Type of Test: Quantitative, immunonephelometry   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: Dimension Vista $^ \mathrm { \textregistered }$ $\beta _ { 2 }$ -Microglobulin Flex $^ \mathrm { \textregistered }$ reagent cartridge (B2MIC) Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Calibrator (CAL) Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control Medium (M) Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control High (H)

# G. Regulatory Information:

1. Regulation section: 21 CFR $\$ 866.5630$ Beta-2-Microglobulin Immunological Test System 21 CFR $\$ 862.1150$ , Calibrator 21 CFR $\$ 862.1660$ , Quality Control Material (Assayed and Unassayed)   
2. Classification: Class II, Devices and Calibrator Class I, Quality Control Material   
3. Product code: JZG, System, Test, Beta-2-Microglobulin Immunological JIX, Calibrator, Multi-Analyte Mixture JJY, Multi-Analyte Controls, All kinds (Assayed and Unassayed)   
4. Panel: Immunology (82) Chemistry (75)

# H. Intended Use:

1. Intended use(s): Dimension Vista $^ \mathrm { \textregistered }$ System $\beta _ { 2 }$ -Microglobulin Flex $^ \mathrm { \textregistered }$ reagent cartridge: The B2MIC method is an in vitro diagnostic test for the quantitative determination of $\beta _ { 2 }$ -Microglobulin in human serum or heparinized or EDTA plasma on the Dimension Vista $^ \mathrm { \textregistered }$ System. Measurements of $\beta _ { 2 }$ -Microglobulin aid in the diagnosis of renal dysfunction.

Dimension Vista $^ \mathrm { \textregistered }$ System Protein 1 Calibrator: PROT 1 CAL is an in vitro diagnostic product for the calibration of the $\beta _ { 2 }$ - Microglobulin (B2MIC), C3 complement (C3), C4 complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), Prealbumin/Transthyretin (PREALB) methods on the Dimension Vista $^ \mathrm { \textregistered }$ System.

Dimension Vista $^ \mathrm { \textregistered }$ System Protein 1 Control M (medium):   
PROT1 CON M is an assayed intralaboratory quality control for assessment of precision and analytical bias in the determination of $\beta _ { 2 }$ -Microglobulin (B2MIC), C3 complement (C3), C4 complement (C4), Immunoglobulin A (IGA),   
Immunoglobulin G (IGG), Immunoglobulin M (IGM), Prealbumin/Transthyretin (PREALB) on the Dimension Vista $^ \mathrm { \textregistered }$ System. Dimension Vista $^ \mathrm { \textregistered }$ System Protein 1 Control H (high):   
PROT1 CON H is an assayed intralaboratory quality control for assessment of precision and analytical bias in the determination of $\beta _ { 2 }$ -Microglobulin (B2MIC), C3 complement (C3), C4 complement (C4), Immunoglobulin A (IGA),   
Immunoglobulin G (IGG), Immunoglobulin M (IGM), Prealbumin/ Transthyretin (PREALB) on the Dimension Vista $^ \mathrm { \textregistered }$ System.

Calibrators and controls are not included in the device and are sold separately.

2. Indication(s) for use: Same as Intended Use.   
3. Special conditions for use statement(s): For prescription use only.   
4. Special instrument requirements: Dimension Vista $^ \mathrm { \textregistered }$ System (k051087)

# I. Device Description:

Dimension Vista $^ \mathrm { \textregistered }$ System B2MIC Flex $^ \mathrm { \textregistered }$ reagent cartridge carton contains 2 cartridges (12 wells per cartridge which generates approximately 100 tests/cartridge) with mouse monoclonal antiserum to human $\beta _ { 2 }$ -Microglobulin, phosphate buffer, and polyethylene glycol sorbitan monolaurate. Reagent is in ready-to-use liquid form.

Dimension Vista $^ \mathrm { \textregistered }$ System Protein 1 Calibrator carton contains 6 vials $2 \mathrm { m L }$ per vial), with a multi-analyte human serum based product containing $\beta _ { 2 }$ -Microglobulin, C3, C4, IgA, IgG, IgM and Prealbumin. Reagent is in ready-to-use liquid form.

Dimension Vista $^ \mathrm { \textregistered }$ System Protein 1 Control M, and Control H cartons contain 6 vials per carton $2 \mathrm { m L }$ per vial), with a multi-analyte human serum based products containing $\beta _ { 2 }$ -Microglobulin, C3, C4, IgA, IgG and IgM and Prealbumin. Reagents are ready-to-use liquid form.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dade Behring N Latex $\beta _ { 2 }$ -Microglobulin assay Dade Behring N Protein Standard SL Dade Behring N/T Protein Controls SL   
2. Predicate 510(k) number: k002731 (Antisera) k012470 (Protein Standard) k012468 (Controls)   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Dimension Vista® SystemB2-Microglobulin Flex®reagent cartridge</td><td rowspan=1 colspan=1>Dade Behring N LatexB2-Microglobulinassay</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationfor Use</td><td rowspan=1 colspan=1>An in vitro diagnostic testfor the quantitativedetermination of B2-Microglobulin to aid in thediagnosis of renaldysfunction</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Immunonephelometry</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>B2-Microglobulinantisera mammal source</td><td rowspan=1 colspan=1>Mouse Monoclonal</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Dimension Vista®System B2-MicroglobulinFlex® reagent cartridge</td><td rowspan=1 colspan=1>Dade Behring N LatexB2-Microglobulin assay</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum and plasma (EDTA;lithium and sodium heparin)</td><td rowspan=1 colspan=1>Serum, plasma (EDTA;sodium, lithium andammonium heparin), urineand CSF</td></tr><tr><td rowspan=1 colspan=1>Reportable range forserum and plasma</td><td rowspan=1 colspan=1>0.72 - 23.0 mg/L</td><td rowspan=1 colspan=1>0.70 - 23.0 mg/L</td></tr><tr><td rowspan=1 colspan=1>Reportable range forurine</td><td rowspan=1 colspan=1>Urine is not a matrix</td><td rowspan=1 colspan=1>0.2 - 6.0 mg/L</td></tr><tr><td rowspan=1 colspan=1>International Referencestandard material</td><td rowspan=1 colspan=1>Traceable to Highlypurified proteins 1 stInternational Standard(NIBSC)</td><td rowspan=1 colspan=1>Traceable to HighlyPurified Proteins</td></tr><tr><td rowspan=1 colspan=1>Storage conditions</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 21 days on boardanalyzer</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 4 weeks at 2-8°C</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Dimension Vista® System</td><td rowspan=1 colspan=1>Dade Behring BNTMSystems</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Dimension Vista® SystemProtein 1 Calibrator</td><td colspan="1" rowspan="1">Dade Behring NProtein Standard SL</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationfor Use</td><td colspan="1" rowspan="1">For the calibration ofspecific serum proteinassays</td><td colspan="1" rowspan="1">Establishment of thereference curves for thedetermination of specificserum protein assays</td></tr><tr><td colspan="1" rowspan="1">Material source</td><td colspan="1" rowspan="1">Human serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent preparation</td><td colspan="1" rowspan="1">Ready-to-use, liquid</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Dimension Vista®System Protein 1Calibrator</td><td rowspan=1 colspan=1>Dade Behring N ProteinStandard SL</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>7 analytes: B2-Microglobulin, C3, C4,IgA, IgG, IgM andPrealbumin</td><td rowspan=1 colspan=1>27 analytes: IgG, IgG1,IgG2, IgG3, IgG4, IgA,IgM, IgE, C3c, C4,Transferrin, Albumin,α1-antitrypsin,α2-macroglobulin,haptoglobin, α1-acidglycoprotein, Prealbumin,hemopexin, ceruloplasmin,RbP, Ig/L-chain Kappa,Ig/L-chain Lambda,soluble transferrinreceptor, ferritin, B2-microglobulin, total protein</td></tr><tr><td rowspan=1 colspan=1>International Referencestandard material</td><td rowspan=1 colspan=1>Traceable to Highlypurified proteins 1stInternational Standard(NIBSC)</td><td rowspan=1 colspan=1>Traceable to HighlyPurified Proteins</td></tr><tr><td rowspan=1 colspan=1>Storage conditions</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 9 days on boardanalyzer</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 14 days at 2-8°C</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Dimension Vista® System</td><td rowspan=1 colspan=1>Dade Behring BNTMSystems</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Dimension Vista® SystemProtein 1 Control</td><td colspan="1" rowspan="1">Dade Behring N/TProtein Controls SL</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationfor Use</td><td colspan="1" rowspan="1">Assayed intralaboratoryquality controls forassessment of precision andanalytical bias in thedetermination of specificprotein assays</td><td colspan="1" rowspan="1">For use as assayedaccuracy controls andprecision controls in thedetermination of specificserum protein assays</td></tr><tr><td colspan="1" rowspan="1">Material source</td><td colspan="1" rowspan="1">Human serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent preparation</td><td colspan="1" rowspan="1">Ready-to-use, liquid</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Dimension Vista®System Protein 1 Control</td><td rowspan=1 colspan=1>Dade Behring N/TProtein Controls SL</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>7 analytes: B2-Microglobulin, C3, C4,IgA, IgG, IgM andPrealbumin</td><td rowspan=1 colspan=1>27 analytes: IgG, IgG1,IgG2, IgG3, IgG4, IgA,IgM, IgE, C3c, C4,Transferrin, Albumin,α1-antitrypsin,α2-macroglobulin,haptoglobin, α1-acidglycoprotein, Prealbumin,hemopexin, ceruloplasmin,RbP, Ig/L-chain Kappa,Ig/L-chain Lambda,soluble transferrinreceptor, ferritin, B2-microglobulin, total protein</td></tr><tr><td rowspan=1 colspan=1>Storage conditions</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 9 days on boardanalyzer</td><td rowspan=1 colspan=1>Unopened product:Refrigerate at 2-8°C untilexpired.Opened product: stablefor 14 days at 2-8°C</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Dimension Vista® System</td><td rowspan=1 colspan=1>Dade Behring BNTMSystems</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Medium and High</td><td rowspan=1 colspan=1>Low, Medium, and High</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI/NCCLS, EP 5-A2: Evaluation of Precision Performance of Clin Chem Devices CLSI/NCCLS, EP 7-A2: Interference Testing in Clinical Chemistry CLSI/NCCLS, EP 9-A2: Method Comparison and Bias Estimation

L. Test Principle:

Polystyrene particles coated with specific antibodies to human $\beta _ { 2 }$ -Microglobulin are aggregated when mixed with samples containing human $\beta _ { 2 }$ -Microglobulin. These aggregates scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Reproducibility testing was done in accordance with CLSI/NCCLS document

EP5-A2, ‘Approved Guideline for Evaluation of Precision Performance of Clinical Devices’. The intra-assay reproducibility was determined by testing six samples in duplicate twice a day for 20 days. The samples included the M and H controls ( $\left. \mathrm { B } _ { 2 } \right.$ -Microglobulin concentration of 1.88 and $4 . 8 6 \mathrm { m g / L }$ respectively), two serum pools (concentrations of 2.13 and $2 0 . 3 5 \mathrm { m g / L } $ ) and two plasma pools (concentrations of 1.76 and $5 . 6 9 \mathrm { m g / L }$ ). The controls had $\% \mathrm { C V }$ ranging from $2 . 0 7 \%$ to $2 . 5 7 \%$ , the serum pools $2 . 1 3 \%$ to $3 . 0 1 \%$ and the plasma pools $1 . 9 7 \%$ to $2 . 2 2 \%$ .

The inter-assay reproducibility was determined by testing the same six samples in duplicate twice a day for 20 days. The $\% \mathrm { C V }$ for the controls ranged from $3 . 1 0 \%$ to $3 . 5 6 \%$ , the sera pools $3 . 2 3 \%$ to $4 . 0 8 \%$ and the plasma pools $2 . 9 4 \%$ to $3 . 2 8 \%$ . The data are summarized below:

<table><tr><td rowspan=2 colspan=1>Material</td><td rowspan=2 colspan=1>Meanmg/L</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>PROT 1CON M</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>2.57</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>3.56</td></tr><tr><td rowspan=1 colspan=1>PROT 1CON H</td><td rowspan=1 colspan=1>4.86</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>0.151</td><td rowspan=1 colspan=1>3.10</td></tr><tr><td rowspan=1 colspan=1>Serum pool</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>3.23</td></tr><tr><td rowspan=1 colspan=1>Serumpool</td><td rowspan=1 colspan=1>20.35</td><td rowspan=1 colspan=1>0.612</td><td rowspan=1 colspan=1>3.01</td><td rowspan=1 colspan=1>0.831</td><td rowspan=1 colspan=1>4.08</td></tr><tr><td rowspan=1 colspan=1>Plasmapool</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>2.94</td></tr><tr><td rowspan=1 colspan=1>Plasma pool</td><td rowspan=1 colspan=1>5.69</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.186</td><td rowspan=1 colspan=1>3.28</td></tr></table>

# $b$ . Linearity/assay reportable range:

Linearity across the assay range was confirmed by testing a calibrator with high concentration $( 3 7 . 4 2 \mathrm { m g / L } )$ of $\beta _ { 2 }$ -Microglobulin. This calibrator was serially diluted 6 times with System Diluent down to the lower measuring range $( 0 . 6 6 \mathrm { m g / L } )$ . Each dilution was tested in replicates of three.

The linear regression analysis was performed. The acceptance criteria for the slope (0.9 and 1.1) and correlation of coefficient ${ \ge } 0 . 9 5$ were met. (Slope $=$ 0.973, Intercept $= 0 . 0 8 7$ , Correlation coefficient $= 1 . 0 0$ . See figure below). Linearity was observed between 0.66 to $3 7 . 4 2 \mathrm { m g / L }$ . Reportable range for the device was set at $0 . 7 2 - 2 3 . 0 \mathrm { m g / L }$

![](images/ba8086a8d522d9db51082ccbe9069f93d6b4d93f7c13c306e118bc8b8a829800.jpg)  
B2MIC Assay Range Verification

# High Dose Hook Effect:

The possibility of hook occurring when using the Dimension Vista $^ \mathrm { \textregistered }$ B2MIC assay was evaluated with serum sample above the assay range. The sample was analyzed on both the BN ProSpec $^ \mathrm { \textregistered }$ System and the Dimension Vista $^ \mathrm { \textregistered }$ System and results indicated no hook effect was observed up to $1 2 2 \mathrm { m g / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The calibrator is traceable to the reference material Highly Purified Protein $1 ^ { \mathrm { s t } }$ International Standard (3/17/04 NIBSC).

# Device Stability

The expiration date claims for the reagents are as follows: Unopened reagent cartridges and closed vials:

Dimension Vista $^ \mathrm { \textregistered }$ B2MIC Flex® reagent sealed cartridge – 90 days Dimension Vista $^ \mathrm { \textregistered }$ B2MIC Flex® open well reagent cartridge – 21 days Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Calibrator open vial – 9 days Dimension Vista $^ \mathrm { \textregistered }$ Protein 1 Control M and H open vial – 9 days

d. Detection limit:

Detection limit $( 0 . 7 2 \mathrm { m g / L } )$ ) represents the lower limit of the reportable range of $\beta _ { 2 }$ -Microglobulin.

The analytical sensitivity is defined as the minimal detectable level of analyte, which can be distinguished from zero. The value was calculated as the mean value of twenty replicates of System Diluent plus two standard deviations. It was determined to be $0 . 1 7 6 \mathrm { { m g / L } }$ .

e. Analytical specificity:

Interference testing was performed according to CLSI document EP7A2, ‘Interference testing in Clinical Chemistry’ guidance. No significant

interference was observed in the presence of the following interferents: Bilirubin (conjugated and unconjugated) up to $6 0 \mathrm { m g / d L }$ , Hemoglobin up to $1 0 0 0 \mathrm { m g / d L }$ , Triglycerides up to $1 3 1 3 \mathrm { m g / d L }$ , Creatinine up to $3 0 \mathrm { m g / d L }$ , Albumin up to $6 0 0 0 \mathrm { m g / L }$ , Immunoglobulin G $\mathrm { ( I g G ) }$ up to $5 0 0 0 \mathrm { m g / L }$ , Urea up to $5 0 0 \mathrm { m g / d L }$ , Cholesterol up to $5 0 0 \mathrm { m g / d L }$ , Uric Acid $1 6 \mathrm { m g / d L }$ , Rheumatoid factor up to $5 0 0 \ \mathrm { I U / m L }$ , Total Protein up to $1 2 \ : \mathrm { g / L }$ .

Non-interfering substances section of the device package insert provides a list of drugs and other exogenous substances that do not interfere with the assay.

$f .$ Assay cut-off: Not Applicable.

2. Comparison studies:

a. Method comparison with predicate device: The table below shows the comparison of 71 serum and 72 plasma samples ranging from 0.81 to $2 2 . 6 9 \mathrm { m g / L }$ $\beta _ { 2 }$ -Microglobulin that were tested with the Dimension Vista™ $\beta _ { 2 }$ -Microglobulin assay and the predicate device BN ProSpec $^ \mathrm { \textregistered }$ System. Regression analysis of these samples is summarized in the table below:

<table><tr><td></td><td>N</td><td>Slope (95%CI)</td><td>Intercept (95%CI)</td><td>r</td></tr><tr><td>Dimension Vista® vs. BN ProSpec®</td><td>143</td><td>0.942 (0.931, 0.954)</td><td>-0.029 (-0.062, 0.011)</td><td>0.998</td></tr></table>

$b$ . Matrix comparison:

Sera and plasma (EDTA; lithium and sodium heparin) samples, covering the $\beta _ { 2 }$ -Microglobulin assay measuring range $( 1 . 0 1 - 2 1 . 7 8 \mathrm { m g / L } )$ were compared to determine if any significant bias existed between matrices. The correlation coefficients were acceptable and no bias was observed. Regression analyses of the comparison results are summarized below:

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>Lithium heparin plasma vs. serum</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.998*</td></tr><tr><td rowspan=1 colspan=1>Sodium heparinplasma vs. serum</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.997**</td></tr><tr><td rowspan=1 colspan=1>EDTA plasma VS. serum</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.998***</td></tr></table>

\* The range of $\beta _ { 2 }$ -Microglobulin values in the correlation study was $1 . 0 5 { - } 2 1 . 7 8 \ \mathrm { m g / L }$ $^ { * * }$ The range of $\beta _ { 2 }$ -Microglobulin values in the correlation study was $1 . 0 7 { - } 2 1 . 0 8 \mathrm { m g / L }$ $^ { \ast \ast \ast }$ The range of $\beta _ { 2 }$ -Microglobulin values in the correlation study was $1 . 0 1 { - } 2 1 . 6 4 ~ \mathrm { m g / L }$

![](images/67779923cc012af0e6a7e4e35571586d3fbc133ec925334b5b818af5e29c185d.jpg)

3. Clinical studies:

a. Clinical Sensitivity and specificity: Not applicable   
b. Other clinical supportive data: Not applicable.

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The reported expected range for $\beta _ { 2 }$ -Microglobulin in adults $( 0 . 7 - 1 . 8 \mathrm { m g / L } )$ is from literature Lammers M, et al Determination of beta2-microglobulinby $a$ particle-enhanced immunonephelometric assay. Clin Chem 2002; 48: A-119.

Each laboratory should establish its own expected values for $\beta _ { 2 }$ -Microglobulin as performed on the Dimension Vista $^ \mathrm { \textregistered }$ System.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.